Roxithromycin is an oral antibiotic drug used for the treatment of bacterial infections including acute otitis media caused by H. influenzae, M. catarrhalis, or S. pneumoniae in patients with a history of type I penicillin hypersensitivity, pharyngitis and tonsillitis caused by susceptible Streptococcus pyogenes, respiratory tract infections including acute maxillary sinusitis, acute bacterial exacerbations of chronic bronchitis, mild to moderate community-acquired pneuomia, Legionnaires' disease, and pertussis, skin or skin structure infections, helicobacter pylori infection, duodenal ulcer disease, bartonella infections, early Lyme disease, and encephalitis caused by Toxoplasma gondii (in HIV infected patients in conjunction with pyrimethamine). Roxithromycin penetrates the bacterial cell wall of usually gram negative bacteria and act synergistically to inhibit protein synthesis. These compounds act by binding to domain V of the 23S ribosomal RNA of the 50S subunit of the bacterial ribosome. This inhibits translocation of the aminoacyl transfer-RNA, preventing the addition of the next amino acid to the growing polypeptide chain. As a result, protein synthesis is inhibited, preventing bacterial growth and this may even kill the bacteria. Roxithromycin was shown to be more effective against certain Gram-negative bacteria, particularly Legionella pneumophila.

Roxithromycin Anti=Bacterial Pathway References